Oblon Spivak's Post-Grant Team Secures Win at PTAB on Behalf of Ariosa Diagnostics
On Wednesday, the Patent Trial and Appeal Board (PTAB) invalidated a prenatal DNA test patent owned by Stanford University in a victory for Oblon Spivak client Ariosa Diagnostics.
In a final written decision in an inter partes review under the America Invents Act (AIA), the board found that Stanford's U.S. Patent Number 8,296,076 on a method of detecting chromosomal abnormalities in a fetus, such as those related to Down Syndrome, is invalid as anticipated and obvious.
Oblon Spivak’s Post-Grant Patent Practice handles all aspects of USPTO post-issuance proceedings, including practice before the Patent Trial and Appeal Board (PTAB), and appeals to the Court of Appeals for the Federal Circuit (CAFC). Oblon Spivak’s post-grant practitioners are some of the most experienced in the country and the group has settled more inter partes review proceedings than most firms have filed in total.
The Ariosa Diagnostics win was covered by Law360 and can be read by subscribers here.